On November 25, 2019, FDA issued Warning Letters to 15 companies illegally marketing cannabidiol (CBD) products. On the same day, U.S. Food & Drug Administration (FDA) published a revised consumer
Continue Reading FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety
Christopher Van Gundy
Christopher Van Gundy is a partner in the Business Trial Practice Group in the firm's San Francisco office.
What We Learned From FDA’s Public Hearing On Cannabis*
By Christopher Van Gundy & Sarah Blitz on
Posted in FDA, Regulatory Compliance
*This article was originally posted in Law360 on June 4, 2019.
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial plant.
Continue Reading What We Learned From FDA’s Public Hearing On Cannabis*